View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
January 13, 2020

NeuroBo Pharmaceuticals complete Gemphire merger

NeuroBo Pharmaceuticals has completed its previously announced combination with Gemphire Therapeutics.

NeuroBo Pharmaceuticals has completed its previously announced combination with Gemphire Therapeutics.

Free Report
img

2022: So far In Venture Capital

Global investment in 2022 has been majorly dominated by North America, Europe, and Asia Pacific, whereas the Middle East, and South and Central America have recorded low investments comparatively. In light of this, Europe and North America have been identified as the major destinations for Private Equity and Venture Capital (PE/VC) investments.   GlobalData’s whitepaper analyzes which sectors PE/VC firms have been investing in, looking at Technology, Media, and Telecom, with these sectors recording $356 billion and a deal volume of over 10,000 deals in 2022. Healthcare, Financial Services, Business & Consumer Services, and Construction sectors have also seen high investment activity by PE/VC firms, recording a deal value of over $70 billion each.   But what can this mean for you?   Understand how the Deals Database on GlobalData Explorer can be leveraged to:  
  • Track the Aggregate Investment Volumes in PE/VC-Stage firms across geographies and sectors, in addition to viewing the specific deals that drove these volumes
  • Identify the top investors already active in any sector-Geography combinations
  • Assess the Performance of Financial and Legal Advisors, supporting the Dealmaking in any segment of choice (Customizable League tables)
  • Understand what is driving the PE/VC fundraising (Deal Rationale)
  Consult our full report here and optimize your business strategy.
by GlobalData
Enter your details here to receive your free Report.

The combined unit will operate as NeuroBo Pharmaceuticals with NeuroBo shareholders holding a 96.24% stake in the firm.

With the transaction now complete, the merged firm will continue to work on NeuroBo’s clinical-stage drug candidates for neurodegenerative disorders. Richard J Kang will act as president and CEO of the combined company.

Kang said: “We believe that the closing of the merger signifies a transformative event that will provide NeuroBo with the opportunity to achieve its next level of corporate growth as we continue to advance our promising pipeline for neurodegenerative diseases.

“As we look ahead, we have some important milestones on the horizon.”

The company’s lead drug candidate is NB-01 to treat painful diabetic neuropathy (PDN). In Phase-II trial, NB-01 showed improved pain scores from baseline, as measured by a pain study numeric rating scale.

NeuroBo plans to begin a Phase III study of the candidate in the first half of this year, involving 460 subjects with PDN across the US.

The company’s drug candidate portfolio also includes NB-02 designed to treat Alzheimer’s disease, as well as neurodegenerative diseases associated with tau protein pathological dysfunction in the brain.

Furthermore, NeuroBo intends to advance with the development of Gemphire’s gemcabene to treat dyslipidemia.

In July, NeuroBo Pharmaceuticals and Gemphire Therapeutics signed an agreement to merge their operations through an all-stock transaction.

The corporate headquarters of the combined firm is in Massachusetts.

Related Companies

Free Report
img

2022: So far In Venture Capital

Global investment in 2022 has been majorly dominated by North America, Europe, and Asia Pacific, whereas the Middle East, and South and Central America have recorded low investments comparatively. In light of this, Europe and North America have been identified as the major destinations for Private Equity and Venture Capital (PE/VC) investments.   GlobalData’s whitepaper analyzes which sectors PE/VC firms have been investing in, looking at Technology, Media, and Telecom, with these sectors recording $356 billion and a deal volume of over 10,000 deals in 2022. Healthcare, Financial Services, Business & Consumer Services, and Construction sectors have also seen high investment activity by PE/VC firms, recording a deal value of over $70 billion each.   But what can this mean for you?   Understand how the Deals Database on GlobalData Explorer can be leveraged to:  
  • Track the Aggregate Investment Volumes in PE/VC-Stage firms across geographies and sectors, in addition to viewing the specific deals that drove these volumes
  • Identify the top investors already active in any sector-Geography combinations
  • Assess the Performance of Financial and Legal Advisors, supporting the Dealmaking in any segment of choice (Customizable League tables)
  • Understand what is driving the PE/VC fundraising (Deal Rationale)
  Consult our full report here and optimize your business strategy.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology